Edetate Calcium Disodium Anhydrous

Summary

Edetate Calcium Disodium Anhydrous (CHEMBL1200375) is an approved small-molecule chelator; indicated across 4 conditions including myelodysplastic syndrome and acute myeloid leukemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Chemistry: 374.27 Da · C10H12CaN2Na2O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200375
Name	Edetate Calcium Disodium Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6093170
ChEBI	CHEBI:4757
Molecular formula	C10H12CaN2Na2O8
Molecular weight	374.27
InChIKey	SHWNNYZBHZIQQV-UHFFFAOYSA-J

SMILES: C(CN(CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-].[Na+].[Na+].[Ca+2]

IUPAC name: calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate

ChEBI definition: An organic calcium salt of EDTA diisodium. It is a chelating agent that is used for the treatment of lead poisoning.

Pharmacological roles (ChEBI): geroprotector, chelator, antidote.

Also known as: Adsorbonac, Antallin, Calcium disodium edetate, Calcium disodium edta, Calcium titriplex, Detoxamin, Disodium calcium edta, E-385, E385, Edetamine, Edetate calcium disodium anhydrous, Edta calcium disodium salt

Parent form; salt/anhydrous children: CHEMBL3989522

Patent coverage: 5,143 distinct patent families (13,944 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
chronic myeloid leukemia	1	MONDO:0011996	EFO:0000339

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).